A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects.

Trial Profile

A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2014

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms ADAGIO
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 20 Jun 2013 A post-hoc analysis will be presented at the 17th Annual International Congress of Parkinson's Disease and Movement Disorders, according to a Teva media release.
    • 13 Jun 2010 Results have been presented at the 14th International Congress of Parkinson's Disease and Movement Disorders.
    • 20 Apr 2010 Results from a placebo group substudy reported at AAN 2010, according to a Teva Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top